A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

Conditions

• Plaque Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Deucravacitinib — DRUG
  As per product label

Study Details

The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.

Key Dates

Start date

Jan 20, 2025

Status verified

Apr 2026

Primary completion

Mar 11, 2027

Completion

Mar 11, 2027

Study Design

Enrollment

153 participants (actual)

Arms

• Arm: Participants treated with deucravacitinib
  Adults with moderate plaque psoriasis who are newly initiating deucravacitinib according to the product label

Primary Outcome Measure

Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score [ Time Frame: Week 16 ]

Related Studies

• Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
  EARLY_PHASE1 · Recruiting · Wright State University · Fairborn, Ohio
• Understanding Participation Habits Among Plaque Psoriasis Patients
  Not Yet Recruiting · Power Life Sciences Inc. · San Francisco, California
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
  PHASE3 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
  PHASE1 · Recruiting · Ascletis Pharma (China) Co., Limited · Miami, Florida